

ENANTA Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, Massachusetts
02472

Tel: 617.607.0800
Fax: 617.607.0530
www.enanta.com

FOR IMMEDIATE RELEASE

CONTACT:

Susan Burke, Account Executive
Ronald Trahan Associates, Inc.
508-647-9782, ext. 20



**Enanta Pharmaceuticals appoints Dr. Spiros Jamas as
President, Chief Executive Officer and Director**

**“Compounds from Enanta’s proprietary *Morphed Chemical Entity* (MCE™)
libraries are now ready for broad commercialization, and Dr. Jamas is
the ideal person to lead the development of two near-term opportunities.”**

Peter O. Kliem, COO/EVP, Enanta

CAMBRIDGE, Mass., May 30, 2001 -- Enanta Pharmaceuticals Inc., an emerging biopharmaceutical company, announced today the appointment of Spiros Jamas, Sc.D., as President, Chief Executive Officer and Director, effective immediately.

Peter O. Kliem, a co-founder of the Company, will become Chief Operating Officer and Executive Vice President.

“In the post-genomics era, there will be keen focus on *products*,” said Peter Kliem. “Enanta Pharmaceuticals has developed a pipeline of potential *products* addressing at least two different therapeutic areas -- anti-infective and anti-inflammatory drugs -- that have progressed into preclinical investigation. Consequently, the appointment of Dr. Jamas -- an experienced biotechnology leader who has successfully grown companies from the discovery stage to the clinical development stage with pharmaceutical partnerships -- is a very significant milestone in the evolution of Enanta,” Kliem said.

“I am extremely excited to be joining Enanta Pharmaceuticals at this stage in the Company’s expansion,” added Dr. Jamas. “Enanta has assembled an outstanding research team and is moving rapidly from drug discovery to full-scale drug development. The company has two near-term proprietary programs with blockbuster potential and a versatile platform technology to keep fueling the pipeline,” Dr. Jamas said. “I look forward to helping the Enanta team build a successful drug company.”

Prior to joining Enanta Pharmaceuticals, Dr. Spiros Jamas was President, Chief Executive Officer and Director since 1999 of Boston-based Repair Inc., a privately held biopharmaceutical company developing sustained-release angiogenesis therapies to repair diseased organs and tissues. From 1988-1999, Dr. Jamas was President, Chief Executive Officer and Director of Alpha-Beta Technology, a company he founded to develop medical applications of carbohydrates. During his tenure there, Dr. Jamas raised \$200 million through venture capital, initial public offering (IPO) and follow-on financings; directed two INDs, five Phase I, three Phase II and two Phase III clinical trials; and, acquired another privately held biotechnology company. Dr. Jamas earned a

doctor of science degree in biotechnology at the Massachusetts Institute of Technology (MIT).

more...

Page Two

Enanta Pharmaceuticals, founded in 1998, has raised \$25 million to date in private financings. Investors include: Oxford Bioscience Partners (lead investor), Advent International, TVM TechnoVenture Management, Caduceus Capital, Bank Vontobel, Alpinvest International B.V. and KB Lux Venture Capital.

Headquartered in Cambridge, Mass., Enanta Pharmaceuticals is creating its patented Morphed Chemical Entity (MCE™) libraries by transforming existing drugs, natural products and peptides into novel small-molecule drugs. The Company's initial focus is on MCEs derived from existing drugs that address significant unmet medical needs: (a) antibacterial agents (*macrolides* and *ketolides* to overcome bacterial resistance); and (b) anti-inflammatory drugs for a variety of indications, including asthma, psoriasis and inflammatory bowel diseases. Enanta is also using its proprietary Peptide Morphing™ capability to create improved antiviral drugs for HIV, HCV and HPV.

#####